Stay updated on APG-115 + Pembrolizumab in Metastatic Melanomas Clinical Trial
Sign up to get notified when there's something new on the APG-115 + Pembrolizumab in Metastatic Melanomas Clinical Trial page.

Latest updates to the APG-115 + Pembrolizumab in Metastatic Melanomas Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedMinor admin changes: a new page revision label (v3.4.2) appears, and an outdated government funding notice banner is removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check21 days agoChange DetectedAdded a government funding status notice regarding the NIH Clinical Center's operations and updated the site revision to v3.4.1 (replacing v3.4.0).SummaryDifference0.4%

- Check28 days agoChange DetectedAdded a glossary display and updated QC status wording to 'Last Update Submitted that Met QC Criteria', and added 'No FEAR Act Data' with the revision noted as 'Revision: v3.4.0'. Removed the older labels 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4'.SummaryDifference0.2%

- Check35 days agoChange DetectedThe page's revision note was updated from v3.3.3 to v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check64 days agoChange DetectedThe Locations section was expanded and consolidated to list study sites across multiple states and countries, adding a unified Locations section and updating the revision from v3.3.2 to v3.3.3.SummaryDifference2%

- Check85 days agoChange DetectedThe page shows a minor version update, Revision: v3.3.2, replacing v3.3.1, with no changes to study details, eligibility, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to APG-115 + Pembrolizumab in Metastatic Melanomas Clinical Trial
Enter your email address, and we'll notify you when there's something new on the APG-115 + Pembrolizumab in Metastatic Melanomas Clinical Trial page.